CPIC 2026 | 四家机构成为大会指导单位

上海市科委直属事业单位，成立于1994年，深耕行业近30年。

中心核心职能聚焦生命科学、生物医药领域科技创新和产业发展的相关研究、项目管理服务、科技成果转化、招商引资和企业服务、人才培训，以及人类遗传资源管理服务、实验动物管理等，推动产业高质量发展。

As a public institution directly under the Science and Technology Commission of Shanghai Municipality, the center was established in 1994 and has been deeply engaged in the industry for nearly 30 years. 

Its core functions focus on research, project management services, technology transfer, investment promotion and enterprise services, talent training, as well as human genetic resource management services and laboratory animal management in the fields of life sciences and biomedicine, promoting high-quality industrial development.

上海创新药物研发中心成立于2023年，是聚焦高价值靶点挖掘与药物研发核心领域的专业创新平台。中心紧扣国际科学前沿与国家战略需求，坚持源头探索与自主创新双轮驱动，重点布局神经精神、代谢、肿瘤等重大疾病领域的创新药物研发，攻关前沿变革性技术。

中心一方面积极承接国家重大战略任务，牵头开展产学研联合攻关，搭建成果转化全链条服务体系，推动科研成果快速落地；另一方面深度开展国际合作，与全球知名高校、科研机构、跨国药企建立新药研发全链条协作网络，同时坚持人才引进与培养并举，构建多层次创新人才梯队，筑牢核心竞争力根基。

面向未来，中心将持续深耕生物医药创新领域，致力于建成具有全球影响力的生物医药研发高地，助力我国医药产业创新升级。

Established in 2023, Exeliris is a specialized innovation platform dedicated to high-value target discovery and the development of novel therapeutics. Closely aligned with global scientific frontiers and national strategic priorities, the Center is driven by a dual focus on foundational research and independent innovation. Its core efforts are directed toward addressing major diseases—including neuropsychiatric disorders, metabolic diseases, and oncology—while advancing cutting-edge, transformative technologies.

On one front, Exeliris actively undertakes major national R&D initiatives and leads integrated industry–academia–research collaborations. The Center has established a comprehensive, end-to-end translational ecosystem to accelerate the efficient conversion of scientific discoveries into clinical and industrial applications.

In parallel, Exeliris is deeply engaged in global collaboration, building extensive end-to-end R&D partnerships with leading international universities, research institutions, and multinational biopharmaceutical companies. At the same time, it places strong emphasis on both talent recruitment and development, fostering a multi-tiered talent pipeline to underpin long-term innovation excellence.

Looking ahead, Exeliris remains committed to advancing innovation in biopharmaceutical research. It aspires to become a globally influential R&D hub and a key driver of the continued transformation and upgrading of China’s pharmaceutical industry.

中国首家以全球健康为使命的新型研发转化机构，研究院研发经费由上海市和盖茨基金会共同提供。2025年9月22日，研究院宣布正式启动。研究院发挥非营利组织的独特定位，向全球合作伙伴提供技术支持和资源支撑，促进上海和中国创新成果研发转化并加快进入国际市场，为提升中低收入国家健康福祉、促进全球健康公平贡献力量。

Global Health Innovation Institute, （GHII) is China's first new research and development translation institution dedicated to global health. The Institute's funding is jointly provided by the Shanghai and the Gates Foundation. On September 22, 2025, the Institute announced its official launch.

Leveraging its unique position as a non-profit organization, it provides technical support and resources to domestic and global partners, facilitates the translation of innovative R&D achievements from Shanghai and China, and accelerates their entry into international markets, contributing to improved health and well-being in low- and middle-income countries and the advancement of global health equity.

上海国生产教融合创新中心是由复旦大学牵头、联合复星医药等16家单位共同发起的民办非企业独立法人机构，由上海市民政局主管、上海市教委为业务主管单位，实行理事会领导下的主任负责制。中心以深化产学研合作、赋能生物产业创新发展为宗旨，聚焦生物制造与生物技术领域，开展人才培养、科研攻关、概念验证、成果转化等业务，致力打造长三角生物经济核心引擎与全球生物技术策源地。

The Shanghai National Industry-Education Integration Innovation Center is an independent non-profit legal entity initiated by Fudan University in collaboration with 16 organizations including Fosun Pharma.  The center operates under the supervision of Shanghai Civil Affairs Bureau with the Shanghai Municipal Education Commission as its business supervisory authority. It adopts a director responsibility system under the leadership of the board of directors.

With the mission of deepening industry-academia-research collaboration and empowering innovative development in the biotech industry, the center focuses on the fields of biomanufacturing and biotechnology. Its operations include talent cultivation, scientific research breakthroughs, proof-of-concept validation, and technology commercialization, aiming to establish itself as a core engine for the bioeconomy in the Yangtze River Delta region and a global source of biotechnology innovation.

(上下滑动查看更多）